Back to Stocks

EZRA

Reliance Global Group, Inc.
8 filings tracked
financialsinsurance brokerageMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Reliance Global Group is evolving from a traditional insurance aggregator into a diversified venture builder.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of transformation, the consolidated financials reveal a company struggling with fundamental viability. Reliance Global Group reported a $1.47 million net loss for the quarter, and its operating activities were cash-negative, consuming $571,000.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every EZRA filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-Q paints a picture of a company at a critical crossroads, attempting to pivot from a stable but slow-growth insurance model to a high-risk, high-reward technology holding company. The operational improvement in the insurance segment is a positive signal, but it is currently overshadowed by the consolidated net loss and the speculative nature of the new strategic ventures. The success of the "Scale51" model depends entirely on the company's ability to successfully commercialize quantum and life science technologies—areas where it has limited experience. For investors, the immediate focus is on the execution of the reverse stock split and the subsequent ability to maintain the $1.00 minimum bid price. While the $50 million credit facility provides a theoretical safety net, the actual liquidity remains tight. The tension between the organic growth of the insurance engine and the cash-burn of the strategic ventures will determine if EZRA is a visionary transformation or a series of speculative gambles funded by a shrinking core.

Selected Quarter

Core Takeaway

The company is successfully optimizing its core insurance business but is now betting heavily on speculative technology and life science ventures.

Investor Lens

Can the cash flow from the insurance business scale fast enough to support the capital requirements of the Scale51 tech strategy?

Watch Next

Nasdaq compliance status following the May 19, 2026 reverse stock split effective date.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.23Q1 '26 (10-K)+0.10Q2 '26 (10-Q)

Signal Timeline

28 of 31
Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%
bearishMay 7

Reported a consolidated net loss of $1.47 million for the quarter.

earnings miss
70%
bullishMay 7

Insurance segment net income grew 39% due to aggressive cost cutting.

margin expansion
60%
bullishMay 7

Secured a $50 million equity line of credit to fund M&A and operations.

capital raise
50%
neutralMay 7

Initiated strategic investments in Enquantum and Innervate as part of Scale51 strategy.

acquisition
40%

Filing History

10-QMay 7, 2026
Expand Sequence

The 10-Q paints a picture of a company at a critical crossroads, attempting to pivot from a stable but slow-growth insurance model to a high-risk, high-reward technology holding company. The operational improvement in the insurance segment is a positive signal, but it is currently overshadowed by the consolidated net loss and the speculative nature of the new strategic ventures. The success of the "Scale51" model depends entirely on the company's ability to successfully commercialize quantum and life science technologies—areas where it has limited experience. For investors, the immediate focus is on the execution of the reverse stock split and the subsequent ability to maintain the $1.00 minimum bid price. While the $50 million credit facility provides a theoretical safety net, the actual liquidity remains tight. The tension between the organic growth of the insurance engine and the cash-burn of the strategic ventures will determine if EZRA is a visionary transformation or a series of speculative gambles funded by a shrinking core.

10-KMar 26, 2026
Expand Sequence

The recent 10-K/A filing serves as a critical update to the company's corporate governance, specifically adding a Compensation Recovery Policy to its exhibits. While the filing is primarily administrative, it underscores the company's ongoing efforts to formalize internal controls amidst a period of rapid structural change. The overarching tension for investors remains the trade-off between the company's ambitious M&A trajectory and its fragile financial foundation. Ultimately, the impact of the filing highlights a company in transition. The ability of Reliance Global Group to convert its aggressive acquisition spree into a cohesive, profitable platform will determine if it is a successful turnaround play or a cautionary tale of over-leverage. Investors are left to weigh the potential for a massive re-rating against the very real risk of equity wipe-out due to the company's punitive financing terms.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.